Merck Kgaa · XETR:MRK
Merck Kgaa — Q1 2025 Earnings Presentation
13 slides from Merck Kgaa's earnings presentation, 2025
Slide 1: Company Continues to Deliver Growth in Turbulent Times
Q1 2025 Results Company Continues to Deliver Growth in Turbulent Times Merck KGaA Darmstadt, Germany
Slide 2: Q1 2025: Company continues to deliver growth in all three business sectors
1 Q1 2025: Company continues to deliver growth in all three business sectors. 2 Double-digit growth in Process Solutions, strong CM&E sales and continued semiconductor materials demand. 3 Confident & well-positioned to achieve sustainable growth in 2025. Merck KGaA Darmstadt, Germany
Slide 3: Disclaimer
Disclaimer Publication of Merck KGaA, Darmstadt, Germany. In the United States and Canada the group of companies affiliated with Merck KGaA, Darmstadt, Germany operates under individual business names (EMD Serono, Millipore Sigma, EMD Performance Materials). To reflect such fact and to avoid any mis
Slide 4: Highlights: Company Continues to Deliver Growth in Turbulent Times
Highlights: Company Continues to Deliver Growth in Turbulent Times Operations Group Financials Q1 YoY organic sales growth1 Life Science: Sales growing +3% driven by strong PS growth of +11% Very strong YoY improvement in PS orders Q1 organic sales: +2.5% SLS down -2% with headwinds from US po
Slide 5: Financial Overview
FInancIaL OvervIew Merck KGaA Darmstadt, Germany
Slide 6: Q1 2025: Overview
Q1 2025: Overview Key figures Comments [€m] Q1 2024 Q1 2025 Δ Sales up +3%, driven by org. growth with modest support from FX / portfolio effects Net sales 5,120 5,280 3.1% All sectors contributing org. sales growth EBITDA pre 1,454 1,535 5.6% Margin (in % of net sales) 28.4% 29.1% 0.7pp EBITD
Slide 7: Life Science Q1: Low-teens Process Solutions Growth, Validating Ongoing Recovery
Life Science Q1: Low-teens Process Solutions Growth, Validating Ongoing Recovery Life Science P&L Net sales bridge [€m] IFRS Pre €2,144 m 2.5% 0.6% 0.3% €2,218 m Q1 2024 Q1 2025 Q1 2024 Q1 2025 Net sales 2,144 2,218 2,144 2,218 M&S -551 -555 -545 -554 +0.0% Q1 2024 Organic Currency Portfolio Q1 2025
Slide 8: Healthcare Q1: Continued Profitable Growth Driven by CM&E, Erbitux and Mavenclad
Healthcare Q1: Continued Profitable Growth Driven by CM&E, Erbitux and Mavenclad Healthcare P&L Net sales bridge [€m] IFRS Pre €2,048 m 3.4% 0.0% €2,114 m -0.2% Q1 2024 Q1 2025 Q1 2024 Q1 2025 Net sales 2,048 2,114 2,048 2,114 M&S -398 -411 -395 -411 Q1 2024 Organic Currency Portfolio Q1 2025 Admin
Slide 9: Electronics Q1: Semiconductor Materials is the Key Growth Driver
Electronics Q1: Semiconductor Materials is the Key Growth Driver Electronics P&L Net sales bridge €928 m 0.6% 0.9% 0.6% €948 m [€m] IFRS Pre Q1 2024 Q1 2025 Q1 2024 Q1 2025 Net sales 928 948 928 948 M&S -138 -142 -138 -139 +0.0% Q1 2024 Organic Currency Portfolio Q1 2025 Admin -37 -48 -32 -36 R&D -7
Slide 10: Outlook & Guidance
ouTLook & GuIDance Merck KGaA Darmstadt, Germany
Slide 11: Group Full-year 2025 guidance
Group Full-year 2025 guidance Net sales: Organic: +2% to +6% YoY FX: -3% to +0% YoY ~€20.9 – €22.4 bn EBITDA pre: Organic: +2% to +7% YoY FX: -5% to -2% YoY ~€5.8 – €6.4 bn EPS pre: ~€7.90 – €9.00 11 Q1 2025 Results Presentation | May 15, 2025
Slide 12: 2025 Business Sector Guidance
2025 Business Sector Guidance1 Net sales EBITDA pre Life Science Organic: +2% to +6% YoY Organic:+1% to +7% YoY FX: -3% to +0% YoY FX: -4% to -1% YoY ~€8.80 bn to €9.40 bn ~€2.50 bn to €2.70 bn Driven by Process Solutions Net sales EBITDA pre Healthcare Organic: +2% to +6% YoY Orga
Slide 13: Q1 2025: Company continues to deliver growth in all three business sectors
1 Q1 2025: Company continues to deliver growth in all three business sectors. 2 Double-digit growth in Process Solutions, strong CM&E sales and continued semiconductor materials demand. 3 Confident & well-positioned to achieve sustainable growth in 2025. Merck KGaA Darmstadt, Germany